Minority shareholder opposition to related-party transaction
The proposed scheme to acquire Ster Science injectables business was deferred due to valuation concerns from a long tail of smaller investors, despite majority support.
ONESOURCESPECIALTYPHARMA / Q4-FY26 / risks
Keep the risk register visible.
Onesource Specialty Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Dependence on customer regulatory approvals for revenue ramp
Revenue growth relies on customers obtaining regulatory approvals in various markets; delays could impact sequential improvement.
Capacity ramp-up execution risk
New lines must be qualified and validated on time; any delays could constrain ability to meet robust demand.
Oral semaglutide competition
Oral GLP-1 formulations could capture up to a third of the market, potentially reducing demand for injectable formulations.